The All Wales Medicines Strategy Group (AWMSG) has recommended AbbVie’s Maviret for use within NHS Wales, UK, to treat adults suffering from chronic hepatitis C virus (HCV) infection.

Indicated for HCV infection across all major genotypes (GT1-6), Maviret is a once-daily, ribavirin-free regimen with a combination of 100mg of glecaprevir and 40mg of pibrentasvir, which targets and inhibits proteins required for the viral replication.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Discovered under the firm’s alliance with Enanta Pharmaceuticals, glecaprevir is an inhibitor of NS3/4A, while pibrentasvir inhibits NS5A.

University Hospital of Wales Infectious Diseases & Microbiology consultant Dr Brendan Healy said: “New treatments, such as Maviret, offer patients with all the major genotypes of hepatitis C a chance of clearing the virus with as little as eight weeks of treatment.

“This is good news for patients who now have a number of treatment choices that can benefit their quality of life and health.”

“New treatments, such as Maviret, offer patients with all the major genotypes of hepatitis C a chance of clearing the virus with as little as eight weeks of treatment.”

Healy further added that the cost-effective treatment could make a positive impact on overall public health by minimising the pool of disease and aid the elimination agenda of World Health Organisation (WHO).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Maviret secured marketing authorisation from the European Commission in July this year for the treatment of HCV infection in adult patients without cirrhosis.

The authorisation was supported by results obtained from eight registrational studies carried out under the firm’s clinical development programme in more than 2,300 subjects across 27 countries.

Maviret was reported to have demonstrated a 97% cure rate following eight weeks of treatment.

Image: Hepatitis C virus. Photo: courtesy of BruceBlaus via Wikipedia.